VESALIUS-CV (TIMI 66)

VESALIUS-CV will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.

MAIN RESULTS:
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke

N Engl J Med. 2026 Jan 8;394(2):117-127.

VESALIUS-CV on ClinicalTrials.gov

CONTACT US About VESALIUS

PRIMARY RESULTS PRESENTATION

The Effect of EVolocumab in PatiEntS at High CArdiovascuLar RIsk WithoUt Prior Myocardial Infarction or Stroke-Primary Results of the VESALIUS-CV Study (Bohula, AHA 2025)

OTHER PRESENTATIONS

Evolocumab in Patients without Known Atherosclerosis and with Diabetes-Secondary Analysis from VESALIUS-CV (Marston, ACC 2026)
Evolocumab in patients with prior percutaneous coronary intervention and no prior MI-Results from the VESALIUS-CV trial (Bergmark, EuroPCR 2026)
Lipoprotein(a) Levels, Risk of Cardiovascular Events and Benefit of Evolocumab-Findings from the VESALIUS-CV (TIMI 66) Trial (Monguillon, EAS 2026)
The Effect of EVolocumab in PatiEntS at High CArdiovascuLar RIsk WithoUt Prior Myocardial Infarction or Stroke- High-Risk Diabetes Subgroup Analysis (Leiter, ADA 2026)

PUBLICATIONS

Rationale and Design of the Effect of EVolocumab in PatiEntS at High CArdiovascuLar RIsk WithoUt Prior Myocardial Infarction or Stroke (VESALIUS-CV) Trial. Am Heart J. 2024 Mar:269:179-190.

Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial. JAMA. 2026 Apr 28;335(16):1400-1407.

Lipoprotein(a) Levels, Risk of Cardiovascular Events and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial. Circulation. 2026 May 25. doi: 10.1161/CIRCULATIONAHA.126.080999.